Extended Data Fig. 8: Pharmacological inhibition of METTL3 has no lasting effects on normal haematopoiesis.
From: Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia
a–c, Quantification of LSK (Lin-/Ska1+/c-Kit+) and HSC (LSK/CD150+/CD34-) compartments in bone marrow from WT C57BL/6J mice following 14 consecutive daily treatments with either vehicle or 50 mg/kg STM2457 (mean ± s.d., n = 5). d, Blood count results from animal experiments related to a–c. e, Body weight of mice from animal experiments related to a–d (n = 5). Statistical significance was determined by two-tailed Mann–Whitney U test and box plots showing median, IQR and extremes. f, RNA-mass spectrometry quantification of m6A levels on poly-A+-enriched RNA from healthy bone marrow related to the animal experiments in a–d, following 14 days of consecutive treatments with either vehicle or 50 mg/kg STM2457 (mean ± s.d., n = 5). HSC, haematopoietic stem cells; two-tailed Student’s t-test; n.s., not significant.
